| Literature DB >> 16697684 |
Gabriela Rosas1, Gladis Fragoso, Natalia Ainciart, Fernando Esquivel-Guadarrama, Angélica Santana, Raúl J Bobes, Oscar Ramírez-Pliego, Andrea Toledo, Carmen Cruz-Revilla, Gabriela Meneses, Paula Berguer, Fernando A Goldbaum, Edda Sciutto.
Abstract
Brucella lumazine synthase (BLS) has been previously used with success as a delivery system for systemic immunization against murine cysticercosis. We herein determined the usefulness of BLS as a new antigen-delivery system and mucosal-adjuvant using KETc1, one of the peptides of the anti-cysticercosis vaccine. A protection of up to 98% was induced when KETc1 was used as a chimera fused to BLS. Used as adjuvant of KETc1, BLS also induced a high level of protection (79%), which did not significantly differ from that induced by the cholera toxin (74%). KETc1 and BLS administered separately also reduced the parasite load. KETc1 administered orally as a chimera, and to a lesser extent with BLS as adjuvant, elicited IgG and IgA specific antibodies, which were detectable both in fecal extracts and in sera, and increased B and CD4 activated cells. BLS-KETc1 also increased the levels of transcription of TNF-alpha, IL-2 and IFNgamma in Peyer's patches, and in spleen, only increased TNF-alpha was observed. Overall, these results showed that BLS can be used as both an antigen-carrier and as an adjuvant in the design of new oral subunit vaccines.Entities:
Mesh：
Substances：
Year: 2006 PMID： 16697684 DOI： 10.1016/j.micinf.2005.12.006
Source DB: PubMed Journal: Microbes Infect ISSN： 1286-4579 Impact factor: 2.700